CSI Market
Sign In | Register

Atara Biotherapeutics Inc (ATRA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ATRA quarterly Cash Flow →
Looking at cash flow data from Atara Biotherapeutics Inc through Dec 31 2021 provides insight into Dec 31 2025's financial flexibility across reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income32.69
Depreciation & amortization2.12
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense-90.80
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories10.66
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation9.75
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.00
Investment Income Amortization Of Premium-
Investment Income Net Amortization Of Discount And Premium0.26
Non Cash Research And Development Expenses-
Write Off Of Property And Equipment-
Increase Decrease In Accrued Research And Development-7.90
Debt Instrument Increase Accrued Interest-
Settlement Of Asset Retirement Obligations Through Noncash Payments Amount-
Increase Decrease In Operating Lease Assets-
Non Cash Operating Lease Expense5.00
Increase Decrease In Operating Lease Liabilities6.17
Income taxes0.00
Gain (Loss) on Sale of Properties0.00
Accounts Receivable-5.09
Increase (Decrease) in Accounts Payable-4.24
Increase (Decrease) in Other Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.00
Other Working Capital-4.50
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-5.05
Discontinued operations0.00
Net Cash flow from Operating Activities-50.94
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.95
Short-term Investments Proceeds17.20
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments To Acquire Investments And Accrued Interest-
Transfers To Restricted Cash-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities18.15
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.51
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Issuance Of Common Stock Upon Vesting Of Stock Awards-
Change In Other Long Term Liabilities Related To Non Vested Stock Awards-
Proceeds From Issuance Of Underwritten Public Offering-
Finance Lease Principal Payments-0.25
Proceeds From Issuance Of Pre Funded Warrants In Underwritten Public Offering-
Proceeds From Sale Of Future Royalties Net-
Proceeds From Sale Of Pre Funded Warrants To Purchase Common Stock In A Registered Direct Offering Net14.84
Proceeds From Sale Of Common Stock And Pre Funded Warrants In Registered Direct Offerings-
Proceeds From Sale Of Common Stock And Pre- Funded Warrants In Registered Direct Offerings Net-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities16.10
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-49.99
Total Cash Flow-16.69
4 historic quarters locked

Sign in to unlock the full Atara Biotherapeutics Inc cash flow history.

Sign In Create Free Account

About Atara Biotherapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-108361

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License